BioSpace News Archive

Recipharm, the contract development and manufacturing organisation (CDMO), will enter a project together with long-term Indian partner Sobti family aimed at creating production capacity in India for a range of sterile dosage forms.

Oxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, today announced that data yielded by application of its 3D genome architecture technology platform, EpiSwitch™, will be presented at The Society for Immunotherapy of Cancer’s 34th Annual Meeting.

POXEL S.A., a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, announced an update for PXL065 following a positive meeting with the U.S. Food and Drug Administration in the fourth quarter 2019.

Horizon Discovery Group plc announces an agreement to divest the Group’s animal research models business unit to Envigo RMS LLC (“Envigo”).

Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and Market Access.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized research-driven cannabis extraction, distillation and purification, is pleased to announce that it has won the Manufacturing Business Excellence Award from the Barrie Business Awards.

Mallinckrodt plc, a global biopharmaceutical company, will present at the Jefferies London Healthcare Conference in London on Wednesday, Nov. 20, 2019..

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today certain financial and operational results for the three- and nine-month periods ended September 30, 2019.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced additional supportive data from the first reported analyses of the Phase 3 REGENERATE study examining the effects of obeticholic acid (OCA) on noninvasive assessments of liver fibrosis and patient-reported outcomes (PROs).

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology program, EDP1503, will be presented during the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 6–10, 2019 in National Harbor, Maryland.